UMIN-CTR Clinical Trial

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000013951
Receipt No. R000016257
Scientific Title Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors.
Date of disclosure of the study information 2014/05/20
Last modified on 2020/05/17 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors.
Acronym P2 trial of itraconazole
Scientific Title Phase II study of concurrent chemotherapy with itraconazole in advanced gynecologic tumors.
Scientific Title:Acronym P2 trial of itraconazole
Region
Japan

Condition
Condition Gynecologic cancer
Classification by specialty
Obsterics and gynecology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Tto determine the efficacy and safety of combination chemotherapy with itraconazole for gynecologic malignancy, and to define the molecular profile of the responders.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes PFS, Response rate, OS, AEs, QOL, molecular profiling
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 itraconazole with chemotherapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Female
Key inclusion criteria 1. advanced or metastatic sarcoma
2. symptomatic or radiological recurrence within 6 months after last platinum administration of ovarian, fallopian, peritoneal, endometrial, and/or cervical cancers.
Key exclusion criteria history of gemecitabine or docetaxel
Target sample size 16

Research contact person
Name of lead principal investigator
1st name Hiroshi
Middle name
Last name Tsubamoto
Organization Hyogo College of Medicine
Division name Department of Obstetrics and Gynecology
Zip code 663-8501
Address Mukogawa 1-1, Nishinomiya, Hyogo, 663-8501
TEL +81-798-45-6481
Email tsuba@hyo-med.ac.jp

Public contact
Name of contact person
1st name Hiroshi
Middle name
Last name Tsubamoto
Organization Hyogo College of Medicine
Division name Department of Obstetrics and Gynecology
Zip code 663-8501
Address Mukogawa 1-1, Nishinomiya, Hyogo, 663-8501
TEL +81-798-45-6481
Homepage URL
Email tsuba@hyo-med.ac.jp

Sponsor
Institute Department of Obstetrics and Gynecology, Hyogo College of Medicine
Institute
Department

Funding Source
Organization Hyogo College of Medicine
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Hyogo College of Medicin
Address Mukogawa 1-1, Nishinomiya, Hyogo
Tel +81798456111
Email rinsys@hyo-med.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 05 Month 20 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2014 Year 04 Month 13 Day
Date of IRB
2014 Year 04 Month 13 Day
Anticipated trial start date
2014 Year 05 Month 20 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2014 Year 05 Month 13 Day
Last modified on
2020 Year 05 Month 17 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000016257